In vivo photorelease of GABA in the mouse cortex

Wireless Closed-Loop Optical Regulation System for Seizure Detection and Suppression In Vivo

There are approximately 50 million people with epilepsy worldwide, even about 25% of whom cannot be effectively controlled by drugs or surgical treatment. A wireless closed-loop system for epilepsy detection and suppression is proposed in this study. The system is composed of an implantable optrode, wireless recording, wireless energy supply, and a control module. The system can monitor brain electrical activity in real time. When seizures are recognized, the optrode will be turned on. The preset photosensitive caged compounds are activated to inhibit the seizure. When seizures are inhibited or end, the optrode is turned off. The method demonstrates a practical wireless closed-loop epilepsy therapy system.

Outlook on the Application of Metal-Liganded Bioactives for Stimuli-Responsive Release

Direct metal-liganded bioactive coordination complexes are known to be sensitive to stimuli such as pH, light, ion activation, or redox cues. This results in the controlled release of the bioactive(s). Compared to other drug delivery strategies based on metal complexation, this type of coordination negates a multi-step drug loading methodology and offers customized physiochemical properties through judicious choice of modulating ancillary ligands. Bioactive release depends on simple dissociative kinetics. Nonetheless, there are challenges encountered when translating the pure coordination chemistry into the biological and physiological landscape. The stability of the metal-bioactive complex in the biological milieu may be compromised, disrupting the stimuli-responsive release mechanism, with premature release of the bioactive. Research has therefore progressed to the incorporation of metal-liganded bioactives with established drug delivery strategies to overcome these limitations. This review will highlight and critically assess current research interventions in order to predict the direction that pharmaceutical scientists could pursue to arrive at tailored and effective metal-liganded bioactive carriers for stimuli-responsive drug release.

Photolysis of Caged-GABA Rapidly Terminates Seizures In Vivo: Concentration and Light Intensity Dependence

The therapy of focal epilepsy remains unsatisfactory for as many as 25% of patients. The photolysis of caged-γ-aminobutyric acid (caged-GABA) represents a novel and alternative option for the treatment of intractable epilepsy. Our previous experimental results have demonstrated that the use of blue light produced by light-emitting diode to uncage ruthenium-bipyridine-triphenylphosphine-c-GABA (RuBi-GABA) can rapidly terminate paroxysmal seizure activity both in vitro and in vivo. However, the optimal concentration of RuBi-GABA, and the intensity of illumination to abort seizures, remains unknown. The aim of this study was to explore the optimal anti-seizure effects of RuBi-GABA by using implantable fibers to introduce blue light into the neocortex of a 4-aminopyridine-induced acute seizure model in rats. We then investigated the effects of different combinations of RuBi-GABA concentrations and light intensity upon seizure. Our results show that the anti-seizure effect of RuBi-GABA has obvious concentration and light intensity dependence. This is the first example of using an implantable device for the photolysis of RuBi-GABA in the therapy of neocortical seizure, and an optimal combination of RuBi-GABA concentration and light intensity was explored. These results provide important experimental data for future clinical translational studies.

Dopamine Modulates Delta-Gamma Phase-Amplitude Coupling in the Prefrontal Cortex of Behaving Rats

Dopamine release and phase-amplitude cross-frequency coupling (CFC) have independently been implicated in prefrontal cortex (PFC) functioning. To causally investigate whether dopamine release affects phase-amplitude comodulation between different frequencies in local field potentials (LFP) recorded from the medial PFC (mPFC) of behaving rats, we used RuBiDopa, a light-sensitive caged compound that releases the neurotransmitter dopamine when irradiated with visible light. LFP power did not change in any frequency band after the application of light-uncaged dopamine, but significantly strengthened phase-amplitude comodulation between delta and gamma oscillations. Saline did not exert significant changes, while injections of dopamine and RuBiDopa produced a slow increase in comodulation for several minutes after the injection. The results show that dopamine release in the medial PFC shifts phase-amplitude comodulation from theta-gamma to delta-gamma. Although being preliminary results due to the limitation of the low number of animals present in this study, our findings suggest that dopamine-mediated modification of the frequencies involved in comodulation could be a mechanism by which this neurotransmitter regulates functioning in mPFC.

Influence of the Steric Bulk and Solvent on the Photoreactivity of Ruthenium Polypyridyl Complexes Coordinated to l-Proline

Ruthenium polypyridyl complexes are good candidates for photoactivated chemotherapy (PACT) provided that they are stable in the dark but efficiently photosubstitute one of their ligands. Here the use of the natural amino acid l-proline as a protecting ligand for ruthenium-based PACT compounds is investigated in the series of complexes Λ-[Ru(bpy)₂(l-prol)]PF₆ ([1a]PF₆; bpy = 2,2′-bipyridine and l-prol = l-proline), Λ-[Ru(bpy)(dmbpy)(l-prol)]PF₆ ([2a]PF₆ and [2b]PF₆; dmbpy = 6,6′-dimethyl-2,2′-bipyridine), and Λ-[Ru(dmbpy)₂(l-prol)]PF₆ ([3a]PF₆). The synthesis of the tris-heteroleptic complex bearing the dissymmetric proline ligand yielded only two of the four possible regioisomers, called [2a]PF₆ and [2b]PF₆. Both isomers were isolated and characterized by a combination of spectroscopy and density functional theory calculations. The photoreactivity of all four complexes [1a]PF₆, [2a]PF₆, [2b]PF₆, and [3a]PF₆ was studied in water (H₂O) and acetonitrile (MeCN) using UV–vis spectroscopy, circular dichroism spectroscopy, mass spectrometry, and ¹H NMR spectroscopy. In H₂O, upon visible-light irradiation in the presence of oxygen, no photosubstitution took place, but the amine of complex [1a]PF₆ was photooxidized to an imine. Contrary to expectations, enhancing the steric strain by the addition of two ([2b]PF₆) or four ([3a]PF₆) methyl substituents did not lead, in phosphate-buffered saline (PBS), to ligand photosubstitution. However, it prevented photoxidation, probably as a consequence of the electron-donating effect of the methyl substituents. In addition, whereas [2b]PF₆ was photostable in PBS, [2a]PF₆ quantitatively isomerized to [2b]PF₆ upon light irradiation. In pure MeCN, [2a]PF₆ and [3a]PF₆ showed non-selective photosubstitution of both the l-proline and dmbpy ligands, whereas the non-strained complex [1a]PF₆ was photostable. Finally, in H₂O–MeCN mixtures, [3a]PF₆ showed selective photosubstitution of l-proline, thus demonstrating the active role played by the solvent on the photoreactivity of this series of complexes. The role of the solvent polarity and coordination properties on the photochemical properties of polypyridyl complexes is discussed.

Three ruthenium polypyridyl l-proline complexes with increasing strain (R, R′ = H or Me) were synthesized and their photoreactivities studied in phosphate-buffered saline, pure acetonitrile (MeCN), and water−MeCN mixtures. Depending on the number of methyl groups, on the presence of air, and on the nature of the solvent, either photoisomerization, photooxidation of l-proline, selective photosubstitution, or nonselective photosubstitution was observed.

Combination of Ru(ii) complexes and light: new frontiers in cancer therapy

The synergistic action of light, oxygen and a photosensitizer (PS) has found applications for decades in medicine under the name of photodynamic therapy (PDT) for the treatment of skin diseases and, more recently, for the treatment of cancer. However, of the thirteen PSs currently approved for the treatment of cancer over more than 10 countries, only two contain a metal ion. This fact is rather surprising considering that nowadays around 50% of conventional chemotherapies involve the use of cisplatin and other platinum-containing drugs. In this perspective article, we review the opportunities brought by the use of Ru(ii) complexes as PSs in PDT. In addition, we also present the recent achievements in the application of Ru(ii) complexes in photoactivated chemotherapy (PACT). In this strategy, the presence of oxygen is not required to achieve cell toxicity. This is of significance since tumors are generally hypoxic. Importantly, this perspective article focuses particularly on the Ru(ii) complexes for which an in vitro biological evaluation has been performed and the mechanism of action (partially) unveiled.